Search Results - "Gomon, M."

Refine Results
  1. 1
  2. 2

    Advanced-Therapy Medicinal Products: Challenges for Implementation in Pediatric Clinical Practice by Gomon, Yulia M., Kolbin, Alexey S.

    Published in Voprosy sovremennoĭ pediatrii (25-02-2024)
    “…The article discusses classifications of medicines for gene and cell therapy. Data on medicinal products registered in Russia, as well as in the European Union…”
    Get full text
    Journal Article
  3. 3

    Clinical and economic analysis of Reslizumab use in the treatment of patients with severe allergic eosinophilic asthma by Kolbin, A S, Avdeev, S N, Zhuravleva, M V, Gomon, Yu M, Balykina, Yu E, Matveyev, N V, Proskurin, M A, Fedosenko, S V

    Published in Terapevtic̆eskii arhiv (15-12-2019)
    “…Asthma is a heterogeneous chronic disease of airways. One of its endotypes is eosinophilic asthma, accompanied by both peripheral blood and airway…”
    Get full text
    Journal Article
  4. 4

    Dynamics of Reserve Antimicrobial Drug Consumption in Russian Hospitals: Impact of the COVID-19 Pandemic by Y. M. Gomon, A. A. Kolbin, D. S. Budanov

    Published in Antibiotiki i himioterapiâ (23-10-2023)
    “…The aim of the study is the assessment of the resistance levels dynamics in clinically significant infectious agents based on the consumption dynamics of…”
    Get full text
    Journal Article
  5. 5

    Redescription of Chlorophthalmus corniger, a senior synonym of Chlorophthalmus bicornis (Family: Chlorophthalmidae) by Bineesh, K. K., Akhilesh, K. V., Gomon, M. F., Abdussamad, E. M., Pillai, N. G. K., Gopalakrishnan, A.

    Published in Journal of fish biology (01-02-2014)
    “…Chlorophthalmus corniger is redescribed on the basis of recently collected specimens. The species is redefined as a species of Chlorophthalmus with the lower…”
    Get full text
    Journal Article
  6. 6

    Efficacy of alectinib in comparison with lorlatinib in patients with ALK-positive non-small cell lung cancer: pharmacoeconomic study by Kolbin, A. S., Gomon, Yu. M., Proskurin, M. A., Balykina, Yu. E.

    Published in Farmakoèkonomika (Moskva. Online) (10-11-2023)
    “…Objective: to evaluate the clinical and economic effectiveness of alectinib in comparison with lorlatinib in adult patients with advanced anaplastic lymphoma…”
    Get full text
    Journal Article
  7. 7

    A Systematic Review with Meta-Analysis and Indirect Comparison of the Effectiveness of COVID-19 Anti-Interleukin Therapy by Yu. M. Gomon, A. S. Kolbin, A. M. Fahrutdinova, T. A. Usmanova, F. M. Sultanova, Yu. E. Balykina

    Published in Antibiotiki i himioterapiâ (18-07-2023)
    “…Aim. Evaluation of the effectiveness of anti-interleukin drugs used in the pathogenetic therapy of COVID-19 in relation to the relative risks of 28-day…”
    Get full text
    Journal Article
  8. 8

    Clinical-economic analysis of the target therapy in severe atopic dermatitidis in adults by Kolbin, A. S., Gomon, Y. M., Proskurin, M. A., Balikina, Y. E.

    “…Target therapy of severe atopic dermatitidis (AD) is actual because AD has a high prevalence and social-economic burden. Target therapy consists of monoclonal…”
    Get full text
    Journal Article
  9. 9

    Factors associated with adverse outcome among hospitalized patients with moderate to severe COVID-19 by Mishinova, S. A., Gomon, Yu. M., Kolbin, A. S., Verbitskaya, E. V., Galimov, T. I.

    “…Aims. To consider factors associated with adverse outcome among hospitalized patients with moderate and severe COVID-19. Materials and methods . Data from 345…”
    Get full text
    Journal Article
  10. 10

    Approaches to Assessing the Safety of Medicines during the COVID-19 Pandemic Using the Example of Azithromycin by Gomon, Yu. M., Kasimova, A. R., Kolbin, A. S., Strizheletsky, V. V., Ivanov, I. G., Mazurenko, S. O.

    “…Most of the medicines used to treat the novel coronavirus infection (COVID-19) are either approved under an accelerated procedure or not approved for the…”
    Get full text
    Journal Article
  11. 11

    The real practice of clinical and economic research of drugs included in the Federal Program of High-Cost Nosologies by Kolbin, A. S., Gomon, Yu. M., Kasimova, A. R., Kurylev, A. A., Bem, A. E.

    Published in Farmakoèkonomika (Moskva. Online) (15-04-2022)
    “…Objective : to assess the compliance of the actual practice of conducting clinical and economic research with the requirements applicable in the Russian…”
    Get full text
    Journal Article
  12. 12

    A systematic review of real-world clinical practice data in COVID-19: non-interventional studies by Mishinova, S. A., Gomon, Yu. M., Kolbin, A. S., Strizheletsky, V. V., Ivanov, I. G.

    Published in Farmakoèkonomika (Moskva. Online) (15-04-2022)
    “…Introduction . As defined by the Food and Drug Administration, real-world data (RWD) is data related to a patient's health and/or health care delivery, usually…”
    Get full text
    Journal Article
  13. 13

    Efficiency of Levilimab in patients with moderate and severe COVID-19 by Gomon, Yu. M., Strizheletsky, V. V., Ivanov, I. G., Balykina, Yu. E., Ermolyev, M. V., Kolbin, A.  S., Livshits, M. V., Usmanova, T.  A., Fakhrutdinova, A. M., Konstantinova, Yu. S. , Gubanov, A. P.

    Published in Farmakoèkonomika (Moskva. Online) (21-04-2023)
    “…Objective: evaluation of the clinical and economic efficiency of using Levilimab in the treatment of moderate and severe COVID-19 based on real world data…”
    Get full text
    Journal Article
  14. 14

    Socioeconomic and global burden of COVID-19 by Kolbin, A. S., Gomon, Yu. M., Balykina, Yu. E., Belousov, D. Yu, Strizheletskiy, V. V., Ivanov, I. G.

    “…Relevance . Assessment of the burden of disease provides information on the economic consequences of the disease, allows you to assess the social significance,…”
    Get full text
    Journal Article
  15. 15

    Cystic fibrosis as a social-economic burden by Kolbin, A. S., Gomon, Yu. M., Karpov, O. I., Balykina, Yu. E., Proskurin, M. A.

    “…Cystic fibrosis (CF) is a chronic genetic disease with social significant weight because it influences on social humanitarian part of health and on sources of…”
    Get full text
    Journal Article
  16. 16
  17. 17

    Socio-economic burden of COVID-19 in the Russian Federation by Kolbin, A. S., Belousov, D. Yu, Gomon, Yu. M., Balykina, Yu. E., Ivanov, I. G.

    “…Purpose. Assessment of the socio-economic burden of COVID-19 in the Russian Federation (RF). Materials and methods. Identification and assessment of direct…”
    Get full text
    Journal Article
  18. 18

    Piperacillin-tazobactam: prospects for use in real-world practice by Yu. M. Gomon

    “…A review of the literature concerning the efficacy and safety of combined anti-pseudomonas protected ureidopenicillin piperacillin/tazobactam usage. Randomized…”
    Get full text
    Journal Article
  19. 19

    IMPROVEMENT OF THE TRACHEAL INTUBATION PROCEDURE IN SURGICAL INTERVENTIONS by Gomon, M L, Bondarenko, T V, Terekhovskyi, A I, Vygonyuk, A V, Gomon, N M

    Published in Klinična hìrurgìâ (Kiïv) (2016)
    “…Results of tracheal intubation during anesthesiological support of surgical interventions on facial skull in 127 patients, while presence of operative risk…”
    Get full text
    Journal Article
  20. 20

    ANALYSIS OF CONSUMPTION OF ANTIBACTERIAL DRUGS FOR SYSTEMIC USE IN HOSPITALS OF SAINT PETERSBURG IN 2014–2015 by Gomon, Yu. M., Kurylev, A. A., Kolbin, A. S., Proskurin, M. A., Ivanov, I. G., Sidorenko, S. V., Arepieva, M. A., Sokolov, A. V.

    Published in Zhurnal infektologii (07-10-2018)
    “…Introduction . The overuse of antimicrobial agents, and poor adherence to infection control measures are leading factors in the development of bacterial…”
    Get full text
    Journal Article